Expression of human AR cDNA driven by its own promoter results in mild promotion, but not suppression, of growth in human prostate cancer PC-3 cells

Asian Journal of Andrology

Volumn 9, Issue 2, 2007, Pages 181-188

  Altuwaijri, Saleh ^a,b   Wu, Cheng Chia ^a   Niu, Yuan Jie ^a   Mizokami, Atsushi ^a,c   Chang, Hong Chiang ^a,d   Chang, Chawnshang ^a,e  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^c Department of Urology   (Japan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e Box 626   (United States)

Author keywords

Androgen ablation therapy; Androgen receptor; Apoptosis; Proliferation; Prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; COMPLEMENTARY DNA;

ANDROGEN INDEPENDENT PROSTATE CANCER CELL; APOPTOSIS; ARTICLE; CANCER CELL; CELL CLONE; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOMEGALOVIRUS; HUMAN; HUMAN CELL; MALE; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION;

CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DIHYDROTESTOSTERONE; DNA, COMPLEMENTARY; HUMANS; MALE; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSFECTION;

EID: 33947269319     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1111/j.1745-7262.2007.00258.x     Document Type: Article

References (20)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
2. Perrotti M, Pantuck A, Rabbani F, Israeli RS, Weiss RE. Review of staging modalities in clinically localized prostate cancer. Urology 1999; 54: 208-14.
3. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002; 62: 1008-13.
4. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276-308.
5. Heisler LE, Evangelou A, Lew AM, Trachtenberg J, Elsholtz HP, Brown TJ. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Mol Cell Endocrinol 1997; 126: 59-73.
6. Marcelli M, Haidacher SJ, Plymate SR, Birnbaum RS. Altered growth and insulin-like growth factor-binding protein-3 production in PC3 prostate carcinoma cells stably transfected with a constitutively active androgen receptor complementary deoxyribonucleic acid. Endocrinology 1995; 136: 1040-8.
7. Yuan S, Trachtenberg J, Mills GB, Brown TJ, Xu F, Keating A. Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res 1993; 53: 1304-11.
8. Lindzey J, Grossmann M, Kumar MV, Tindall DJ. Regulation of the 5′-flanking region of the mouse androgen receptor gene by cAMP and androgen. Mol Endocrinol 1993; 7: 1530-40.
9. Deng JH, Yang LP, Wang LS, Zhou DF. Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients. Asian J Androl 2004; 6: 75-7.
10. Zhao ZG, Ma QZ, Xu CX. Abrogation of heat-shock protein (HSP)70 expression induced cell growth inhibition and apoptosis in human androgen-independent prostate cancer cell line PC-3m. Asian J Androl 2004; 6: 319-24.
11. Yang L, Lin HK, Altuwaijri S, Xie S, Wang L, Chang C. APPL suppresses androgen receptor transactivation via potentiating Akt activity. J Biol Chem 2003; 278: 16820-7.
12. Lin HK, Wang L, Hu YC, Altuwaijri S, Chang C. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J 2002; 21: 4037-48.
13. Altuwaijri S, Lin HK, Chuang KH, Lin WJ, Yeh S, Hanchett LA, et al. Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphor-bolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells. Cancer Res 2003; 63: 7106-12.
14. Lin HK, Hu YC, Yang L, Altuwaijri S, Chen YT, Kang H Y, et al. Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J Biol Chem 2003; 278: 50902-7.
15. Yang L, Yeh SD, Xie S, Altuwaijri S, Ni J, Hu YC, et al. Androgen suppresses PML protein expression in prostate cancer CWR22R cells. Biochem Biophys Res Commun 2004; 314: 69-75.
16. Litvinov IV, De Marzo AM, Isaacs JT. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling ?J Clin Endocrinol Metab 2003; 88: 2972-82.
17. Xu X F, Zhou SW, Zhang X, Ye ZQ, Zhang JH, Ma X, et al. Prostate androgen-regulated gene: A novel potential target for androgen-independent prostate cancer therapy. Asian J Androl 2006; 8: 455-62.
18. Kushner PJ, Hort E, Shine J, Baxter JD, Greene GL. Construction of cell lines that express high levels of the human estrogen receptor and are killed by estrogens. Mol Endocrinol 1990; 4: 1465-73.
19. Lin MC, Rajfer J, Swerdloff RS, Gonzalez-Cadavid NF. Testosterone down-regulates the levels of androgen receptor mRNA in smooth muscle cells from the rat corpora cavernosa via aromatization to estrogens. J Steroid Biochem Mol Biol 1993; 45: 333-43.
20. Choi KH, Basma H, Singh J, Cheng PW. Activation of CMV promoter-controlled glycosyltransferase and beta -galactosidase glycogenes by butyrate, tricostatin A, and 5-aza-2′-deoxycytidine. Glycoconj J 2005; 22: 63-9.